• About
  • Contact
Thursday, November 19, 2026
The US Inquirer
No Result
View All Result
  • Login
  • Home
  • National
  • Politics
  • Business
  • Tech
  • Crime
  • World
PRICING
SUBSCRIBE
  • Home
  • National
  • Politics
  • Business
  • Tech
  • Crime
  • World
No Result
View All Result
The US Inquirer
No Result
View All Result
Home Politics

Trump unveils deal for AstraZeneca to cut Medicaid drug prices and join “TrumpRx” site

by Joe Walsh
October 10, 2025
Reading Time: 3 mins read
0
Trump unveils deal for AstraZeneca to cut Medicaid drug prices and join “TrumpRx” site

Pharmaceutical giant AstraZeneca will offer U.S. patients discounted prices for some prescription drugs, President Trump announced Friday, the second major drug company to strike a deal with the Trump administration in recent weeks.

Under the deal, AstraZeneca will offer its drugs to Medicaid patients at “most-favored-nation” prices, meaning the U.K.-based drugmaker will charge no more than the lowest rate offered in other high-income countries, Centers for Medicare and Medicaid Services Administrator Mehmet Oz said in a Friday afternoon Oval Office event. AstraZeneca also promised to offer new prescription drugs at most-favored-nation rates, Oz said.

RELATED POSTS

Trump praises Putin ahead of rare joint meeting with Xi in China

Musk says he’s “not MAGA,” feels “foolish” about midterm spending

AstraZeneca will also list “all primary care medications” on a government website called TrumpRx, and it will offer discounts for some drugs, including lung disease medication, according to Oz. The company said in a statement that it will offer drugs at up to an 80% discount for “eligible patients with prescriptions for chronic diseases.”

TrumpRx — which is set to launch early next year — will not sell drugs directly, but will instead direct consumers to lower prices elsewhere, Oz said. AstraZeneca said the website will allow patients to buy drugs directly from the company at a “reduced cash price.”

The AstraZeneca announcement came less than two weeks after Pfizer reached a similar deal to offer most-favored-nation rates to Medicaid patients and list drugs on TrumpRx.

Policymakers have struggled with high prescription drug prices for decades. Members of both parties have floated proposals to tie drug prices to the typically much lower rates offered in other countries, but the idea faces legal impediments, and drugmakers have argued that price controls could make it harder for them to invest in research.

Mr. Trump has pressed some of the largest pharmaceutical companies to voluntarily offer drugs to Medicaid patients and new drugs at most-favored-nation rates, floating tighter regulations if companies do not comply. Separately, Mr. Trump has threatened 100% tariffs on pharmaceuticals unless drugmakers are in the process of building U.S.-based plants. AstraZeneca on Friday announced plans to invest in U.S. manufacturing and research facilities.

But questions remain about how the president’s deals with drugmakers will work, and who will feel the difference at the pharmacy counter, some experts caution.

Most-favored-nation pricing could have a muted impact on Medicaid patients, experts say, because the program already has a statutory “best price” protection that guarantees the lowest price offered to any U.S. commercial payer. Also, while it could save states money, Medicaid users typically don’t pay out-of-pocket for their medication.

“Medicaid already enjoys ‘best-price’ protection in the sense that they receive the lowest prices charged to any commercial payer in the United States. Therefore, we are starting out at prices well below the averages seen in the U.S. market,” Darius Lakdawalla, chief scientific officer at the University of Southern California’s Schaeffer Center, told CBS News in reaction to the Pfizer deal.

It’s also unclear how many people would benefit from TrumpRx. For uninsured patients or those with high deductibles, such an option could matter, if their prescriptions are among those listed. But most people obtain their medications through insurance.

“The direct-to-patient stuff is, in my view, a sideshow and branding opportunity for Trump,” Sean Sullivan, a health economist at the University of Washington, told CBS News following the Pfizer agreement. “Most patients have drug coverage. … Very few are going to buy medications with cash, unless the drug is not a covered benefit, like weight loss or erectile dysfunction drugs.”

Share6Tweet4Share1

Joe Walsh

Related Posts

Trump praises Putin ahead of rare joint meeting with Xi in China
Politics

Trump praises Putin ahead of rare joint meeting with Xi in China

November 18, 2026
Musk says he’s “not MAGA,” feels “foolish” about midterm spending
Politics

Musk says he’s “not MAGA,” feels “foolish” about midterm spending

November 18, 2026
What to know about Trump’s meeting with Xi in China
Politics

What to know about Trump’s meeting with Xi in China

November 18, 2026
NSA network outage linked to software vulnerability
Politics

NSA network outage linked to software vulnerability

November 18, 2026
Cornyn blocks Trump’s nominee to federal district court in Texas
Politics

Cornyn blocks Trump’s nominee to federal district court in Texas

November 18, 2026
Trump expected to press Xi on Americans detained in China
Politics

Trump expected to press Xi on Americans detained in China

November 18, 2026
Next Post
Maria Corina Machado says her Nobel tells Venezuelans that “we are not alone”

Maria Corina Machado says her Nobel tells Venezuelans that "we are not alone"

How the Israel-Hamas deal came together — a timeline

How the Israel-Hamas deal came together — a timeline

Recommended Stories

Elon Musk’s Starlink and Starshield, and what they mean to Ukraine

Elon Musk’s Starlink and Starshield, and what they mean to Ukraine

October 21, 2026
George W. Bush’s brother says he voted for Talarico in Senate race

George W. Bush’s brother says he voted for Talarico in Senate race

October 21, 2026
Trump expected to press Xi on Americans detained in China

Trump expected to press Xi on Americans detained in China

November 18, 2026

Popular Stories

  • California’s construction industry hurt by ICE raids, builder says

    California’s construction industry hurt by ICE raids, builder says

    207 shares
    Share 83 Tweet 52
  • Trump decrees any attack on Qatar be treated as threat to U.S.

    37 shares
    Share 15 Tweet 9
  • Supreme Court, in birthright citizenship case, limits use of universal injunctions

    20 shares
    Share 8 Tweet 5
  • Smuggler who used tunnel under U.S.-Mexico border pleads guilty

    16 shares
    Share 6 Tweet 4
  • Poll analysis on cost of living and whether political parties have answers

    16 shares
    Share 6 Tweet 4
The US Inquirer

© 2023 The US Inquirer

Navigate Site

  • Home
  • About
  • Contact
  • Ethics
  • Fact Checking and Corrections Policies
  • Copyright
  • Privacy Policy
  • ISSN: 2832-0522

Follow Us

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • National
  • Politics
  • Business
  • Tech
  • Crime
  • World

© 2023 The US Inquirer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?